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ABSTRACT
Pregnancy is associated with an increased risk of
infection related to its associated mechanical
and physiological changes. Sepsis remains
among the top causes of maternal death
worldwide and is associated with substantial
maternal morbidity. However, there are sparse
data on pregnancy-associated severe sepsis
(PASS), related in part to infrequent reports,
varying case definitions and methodological
approach, small cohort size, and often limited
focus on severe sepsis in selected phases of
pregnancy outcomes. Available reports vary, but
indicate that PASS is a rare but likely increasing
complication, and it is more likely to develop
with increased maternal age, among minority
women, the poor, those lacking health
insurance, those with chronic illness or
pregnancy-associated complications, and
following invasive procedures. Obstetric sites
of infection are the most prevalent, but non-
obstetric infections often underlie pregnancy-
associated severe sepsis, though the source of
infection is often not readily apparent during
initial care. Women with PASS can have a
rapidly fatal course and require heightened
clinician vigilance for early diagnosis and
timely effective intervention. Nevertheless,
available reports raise concerns about
prevalent substandard care of these patients,
contributing to adverse outcomes. The case
fatality of PASS appears lower than that in the
general population with severe sepsis, while the
long-term outcomes of survivors remain
unknown.
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INTRODUCTION
The development of incremental morbidity and
progression to death among infected patients
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has been a familiar part of physicians’ practice
long before the microbial etiology was
discovered. However, the transformation in
our understanding of a major part of the
clinical spectrum of infection-related illness to
include a systemic response to infecting
microorganisms has been a relatively recent
event, with the first attempt to standardize
descriptive terminology and its definitions
reported in 1992 by Bone et al. [1].
Sepsis is currently defined as a syndrome
reflecting patient’s systemic response to an
infection [2]. A key component of this
systemic response, though only part of the
spectrum of sepsis manifestations has been the
termed systemic inflammatory response
syndrome (SIRS) [1, 2]. A septic patient is
considered in turn to have severe sepsis if an
infection-related organ dysfunction is present.
Martin et al. [3] estimated that severe sepsis was
present in about 34% of septic patients in the
period of 1995–2000.
The incidence of severe sepsis is rapidly
increasing and it is associated with high
morbidity and mortality. It was estimated that
in 2007 more than 780,000 adults (343 per
100,000) in the United States (US) developed
severe sepsis [4] with an annual increase in rate
of nearly 18% [5]. The global burden of sepsis
has been estimated by Adhikari et al. [6] to
range from 15 to 19 million cases per year.
The most common infection sites in severely
septic patients are respiratory, genitourinary
and abdominal [5, 7]. More than half of
patients with severe sepsis have 2 or more
organ failures (OFs) [4, 5], with pulmonary,
renal, and circulatory systems most commonly
affected [4]. It has been estimated that about
half of the patients with severe sepsis in the US
receive care in the intensive care unit (ICU) [7].
The annual death toll of severe sepsis in the
US was estimated to exceed 210,000 patients per
year in 2007, increasing nearly 180% since 2000
[4]. In addition, survivors of severe sepsis face
long-term consequences of increased mortality
rate and reduced quality of life [8]. The toll of
severe sepsis varies with patients’ demographics
[9–11] and can be adversely affected by the type
of health insurance [12]. The daily cost of care
of septic patients is consistently higher than
those without sepsis at all levels of care [13]. A
recent report estimated that septicemia is the
most expensive condition among hospitalized
patients in the US [14].
Despite its increasing incidence and the
personal and economic burdens, major strides
were made over the past decade in improving
the outlook for patients with severe sepsis. A
landmark study by Rivers et al. [15] introduced
the concept of early goal-directed therapy
(EGDT), demonstrating marked mortality
benefit of early recognition and targeted
circulatory resuscitation in the Emergency
Department. In addition, Kumar et al. [16]
demonstrated that early administration of
appropriate antibiotics is associated with
decline in mortality of patients with septic
shock, while mortality increased by 7.6%
(absolute risk) with each hour of delay. These
two reports were incorporated as part of a
guideline by the surviving sepsis campaign
(SSC), a multinational collaboration of
multidisciplinary professional organizations,
aiming to increase clinicians’ and public
awareness and reduce mortality due to severe
sepsis [17]. Indeed, incorporating SSC guideline-
based bundled care into clinical practice was
associated with reduced mortality [18].
The aforementioned strides have not been
fully realized in the obstetric population.
Pregnancy is associated with increased risk of
infection, in part due to various pregnancy-
related mechanical and physiological changes
[19]. In addition, recent evidence suggests that
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pregnancy is associated with an immunological
shift away from inflammatory processes and
inflammatory cytokines and toward a more
anti-inflammatory immunologic state [20].
These changes may also play a role in the
maternal response to overwhelming infection
and subsequent sepsis [20]. In the 19th century,
infection was the most common cause of
maternal mortality, accounting for 50% of all
maternal deaths [21]. While there has been
tremendous progress in reducing maternal
morbidity and mortality related to pregnancy-
associated infectious complications, the latter
remain a major source of pregnancy-related
mortality in both developing and developed
countries worldwide, reported to be the third to
fourth most common cause of maternal death
[22]. A recent review conducted by the World
Health Organization has estimated the global
burden of maternal sepsis to be more than
6,900,000 cases per year [22].
Among the more basic ongoing challenges in
our understanding the burden of pregnancy-
associated sepsis and development of severe
sepsis among infected patients, many
investigators have noted that clinical reports
often employ imprecise and variable
terminology (often interchangeably) in use of
terms such as septicemia, sepsis, septic shock,
puerperal infection, puerperal fever, or maternal
sepsis [23–26], thus affecting both clinical
practice and present knowledge about
maternal sepsis and severe sepsis in the
obstetric population. Despite the voluminous
body of published research on pregnancy-
associated infections and sepsis, our
contemporary understanding about
pregnancy-associated severe sepsis (PASS)
remains sparse.
There are several explanations for this
knowledge gap. These include the following
limitations of available data: (1) Published
reports to date rarely focused explicitly and/or
primarily on PASS. (2) When reported, studies
often varied in their case definition of severe
sepsis, at times at variance with those used in
the general population, limiting inference and
comparison across studies or with the general
population. (3) Varying methodological
approaches were used in studies of pregnancy-
associated sepsis, further limiting comparisons
across studies. (4) Sample size of reported PASS
patients has been commonly small and often
reflected local rather than population-level
data, further limiting inferences from provided
data. (5) Reports on PASS focused at times on
selected periods of pregnancy (i.e., delivery),
affecting inference about the burden of PASS
across the full spectrum of pregnancy.
The focus of the following review is to
examine the contemporary knowledge of the
epidemiology, demographics, clinical
characteristics, management approach,
resource utilization, and outcomes of women
affected by PASS, and to outline the present and
future challenges in enhancing our insight and
improving care and outcomes of this often
devastating complication of pregnancy. The
care of the fetus and fetal outcomes among
patients with PASS is not part of the present
review and has been described elsewhere [25].
METHODS
Relevant English-language original publications
were sought through search of PubMed and
EMBASE (from January 1992 through March
2014), using the following key terms: sepsis,
severe sepsis, septic shock, septicemia, organ
failure, critical illness, critical care, intensive
care, mortality and pregnancy, abortion,
delivery, puerperium, and miscarriage.
Identified citations were further searched for
additional referenced citations. The following
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publication categories were excluded:
(a) published only in an abstract form,
(b) contained no original data, or (c) did not
specifically describe a group of patients with
severe sepsis associated with pregnancy (i.e., at
the minimum, the number of affected patients,
with or without other characteristics), either as
primary or additional focus of the report. The
search strategy is described in detail in the
Electronic Supplementary Material. Following
removal of duplicate citations, 4,718 articles
were identified, of which 4,710 did not meet
eligibility criteria [reviews (322), reports on
fetal/newborn events (1,933), case reports
(743), and lack of specific description of
maternal severe sepsis (1,712)]. The remaining
eight full-text articles were the focus of the
present review. Descriptive statistics were used.
This article does not involve any new studies





The key characteristics of identified studies
providing epidemiological data on PASS are
presented in Table 1. Several single-center and
regional studies have reported the incidence of
PASS. Mabie et al. [27] reported the incidence of
pregnancy-associated septic shock of 12 per
100,000 deliveries-years in a two-hospital
study. In a regional study, including 25
hospitals in the United Kingdom (UK)
reported by Waterstone et al. [28], the
incidence of PASS was 35 per 100,000
deliveries-years. Finally, a study of PASS in a
tertiary center in Scotland by Acosta et al. [29]
found an incidence of PASS 13 per 100,000
maternities-years. All three studies employed
contemporary definitions of severe sepsis. Their
findings have, however, several limitations.
Data from local facilities may not reflect the
epidemiology in a broader population. In
addition, the sample size was extremely small,
being 18 patients [27], 17 patients [28], and 14
patients [29], affecting precision of overall and
annual [29] incidence estimates. Moreover, the
reported incidence data were spread over
11 years [27] and 23 years [29], during which
the development of PASS and obstetric practice
have likely changed. In addition, the last two
studies [28, 29] may have underestimated the
number of PASS events, due to a restriction of
case definition to culture-positive patients.
However, studies of severe sepsis in the general
population found that about 1 in 4 patients
with severe sepsis can be culture-negative [15].
Finally, the incidence figures of these three
studies are overstated in part due to use of
delivery and maternity denominators in
patients with PASS in the context of all
pregnancy outcomes (i.e., abortion), rather
than the total number of pregnancies among
women at risk during study period.
Three population-level studies on PASS have
been recently reported. Kramer et al. [30] have
performed a retrospective analysis of a
prospective national cohort in the Netherlands
on severe maternal morbidity. The incidence of
PASS was 21 per 100,000 deliveries-years.
However, the validity of this estimate is
limited by numerous methodological
problems. There has been no explicit
definition of sepsis, and severe sepsis was
defined in part by admission to an ICU or any
case of (an undefined) sepsis a physician
considered to be severe morbidity. Specific OF/
dysfunction criteria were not used, which may
have led to misclassification and overestimation
of PASS incidence, as not all ICU admissions
with an infection are due to severe sepsis.
Indeed, as noted in a report by Afessa et al.
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[31], studying obstetric patients in the ICU,
among all obstetric sepsis patients admitted to
the ICU, 49% did not have severe sepsis, when
the authors used the consensus definitions [1].
In addition, as acknowledged by the
investigators, sepsis was not a pre-defined
condition for the prospective data collection,
leading to possible underestimation of PASS
events [30]. The number of PASS patients was
only 78, limiting further the precision of
incidence estimates. Finally, although PASS
events spread over all pregnancy outcomes,
the denominator used for incidence estimates
was the number of deliveries which, as noted
above, may have overestimated the actual
incidence.
A more recent study by Acosta et al. [32]
examined administrative data of live birth
hospitalizations in the state of California. The
reported incidence of PASS was 49
hospitalizations per 100,000 live births-years.
The investigators included hospital length of
stay C90th percentile and/or admission to ICU
as part of case definition of severe sepsis, while
not including OF criteria. It is thus likely that a
substantial number of hospitalizations in that
cohort did not have PASS, resulting in
overestimation of PASS incidence. As noted
earlier, admission to the ICU is not a reliable
surrogate for diagnosis of PASS [31]. A
misclassification of patients in this cohort is
further supported by the markedly low rate of
separately reported, selective (undefined) OFs
(respiratory failure in 10.5%), hospital length of
stay markedly lower than reported by others
[27, 30], and an implausibly low hospital
morality rate (0.8% among non-shock
patients) [32].
Finally, in the largest cohort reported to
date, Bauer et al. [33] have examined a national
administrative data set in the US, focusing on
PASS among delivery hospitalizations. The
incidence of PASS was 9 hospitalizations per
100,000 deliveries-years [33].
The broad range of reported estimates of
PASS incidence in the aforementioned studies
limits our understanding of the contemporary
burden of severe sepsis on the obstetric
population, even when considering only
population-level investigations, and expected
country-specific variation. As noted, varying
case definitions and related methodological
problems affect interpretation of the reported
findings. In addition, the optimal code-based
[i.e., International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-







Mabie et al. [27] 1986–1997 Local/US 18 All
Waterstone et al. [28] 1997–1998 Regional/UK 17 All deliveries after 24 weeks
of gestation
Acosta et al. [29] 1986–2008 Local/UK 14 All
Kramer et al. [30] 2004–2006 National/Netherlands 78 All
Acosta et al. [32] 2005–2007 State/US 791a Live birth hospitalizations
Bauer et al. [33] 1998–2008 National/US 4,158a Delivery hospitalizations
UK United Kingdom, US United States
a Number of hospitalizations
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CM)] case definition of severe sepsis (commonly
using both specific ICD-9-CM codes for severe
sepsis and septic shock and a combination of
sepsis/infection codes, combined with codes of
OF) when using administrative data remains
unsettled, with reported incidence estimates of
severe sepsis in the general population varying
by as much as 3.5-fold across different coding
approaches [34]. It is thus possible that the
study reported by Bauer et al. [33], while using
similar, more conservative, case identification
approach to that in studies of severe sepsis in
the general population, may have substantially
underestimated the burden of PASS.
Nevertheless, when different administrative
case definitions of severe sepsis were used in
the general population, all trended similarly
over time [34]. The study by Bauer et al. [33]
likely represents at present time the broadest
report to date on PASS, with their findings
suggesting that the incidence of PASS among
women during delivery hospitalizations is
markedly lower than that in the general
population with severe sepsis [4].
The available contemporary reports on PASS
have been restricted to Western Europe and the
US. However, as noted earlier [22], the bulk of
the global burden of maternal sepsis and thus of
PASS is affecting disproportionately developing
countries. Thus, data from developing countries
(and other regions) are urgently needed to
better understand the current epidemiology
and the public health impact of PASS in these
areas. Unfortunately, these types of
investigations can be challenging, especially in
resource-limited areas, which often lack
sufficient local epidemiological expertise and
consistent ability by the relatively limited
number of clinicians to accurately diagnose
and report these complications. In addition,
other than the report by Kramer et al. [30], with
its noted limitations, no population-level data
reported on the epidemiology of PASS across the
full spectrum of pregnancy outcomes, including
induced abortion, miscarriage, antepartum and
postpartum hospitalizations.
Only one study to date has described trends
of the incidence of PASS. Bauer et al. [33]
reported that the incidence of PASS rose 10%
per year between 1998 and 2008. The incidence
of PASS increased from 7 to 14 hospitalizations
per 100,000 deliveries over study period.
However, the sources of rising incidence of
PASS remain unclear. Several investigators have
noted the rising incidence of conditions and
procedures leading to maternal severe sepsis
and septic shock, including rising maternal age,
obesity, chronic illness, use of cesarean section,
and use of invasive procedures [25]. While the
aforementioned factors are well associated with
risk of infection, their role in progression from
infection to severe sepsis among obstetric
patients has not been systematically
examined. Indeed, the changes in the
frequency of the aforementioned risk factors
over time among the patients reported by Bauer
et al. [33] have not been reported and require
further study.
Only a few studies on the relative
development of PASS across different phases of
pregnancy have been reported and varied
markedly across cohorts. PASS related to
abortion was reported in 6% [27] to 7% [35].
Development of PASS during the antepartum
period occurred between 33% [30] and 73%
[35], while postpartum PASS events were noted
to account for 20% [35] and up to 92.9% [29] of
all PASS events. The marked differences in the
relative occurrence of PASS across different
phases and outcomes of pregnancy reported in
the aforementioned studies likely reflects
unique local population characteristics,
selection bias, and the small sample size.
Further larger population-level studies are
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needed to better understand the risk of PASS
across non-delivery phases of pregnancy.
The demographic characteristics of women
developing PASS varied with the studied
populations. The average age reported ranged
from 25.8 years [27] to 32 years [30]. The rate of
PASS event in teens and among women older
than 34 years was described infrequently,
reported in 13.6% and 19.9%, respectively
[33]. Black women constituted between 7.1%
[29] and 56% [27] of PASS cohorts in local
studies and between about 9% [32] and 21.2%
[33] in population-level reports, while Hispanic
women were reported in 13% [35] and 56.4%
[32] of PASS events, reflecting regional
variations. Health insurance among US
patients with PASS has been reported in two
studies. Medicaid was the predominant health
insurance (49.8%) of women nationally in the
study by Bauer et al. [33], with 3.6% lacking
health insurance. Acosta et al. [32] reported the
combination of public health insurance/no
insurance in 58.2% of PASS hospitalizations.
Only limited description of chronic
comorbidities in PASS patients has been
reported to date. Local reports [27–29], as well
as a national study [30] did not provide clinical
details on chronic illness. The population-based
study by Acosta et al. [32] documented only
occurrence of diabetes and chronic
hypertension among live birth PASS
hospitalizations. Bauer et al. [33] reported a
broader but still selective range of chronic
comorbidities, with the most common being
congestive heart failure (6%), systemic lupus
(1.5%), and chronic liver disease (0.7%).
However, the investigators provided no data
on the overall frequency of any chronic
comorbidity (of those examined) among PASS
hospitalizations, limiting the inference on the
overall burden of chronic illness from their
findings.
Risk factors for the development of PASS
were examined in several reports. Reported risk
factors included maternal age C35 years [30,
33], low income [30], black race [32, 33],
Medicaid insurance [33] or public insurance/
no insurance [32], tobacco use [28] congestive
heart failure [33], diabetes [32], hypertension
[32], chronic liver disease [33], chronic kidney
disease [33], systemic lupus [33], human
immunodeficiency viral infection [33],
preeclampsia [28, 32], induced labor [29, 30],
cesarean section [28–30], premature rupture of
membranes [30, 33], and retained products of
conception [33]. Of note, obesity was not an
independent risk factor for PASS in the study by
Bauer et al. [33], possibly due to its
underreporting (1.8%) in their population. The
aforementioned predictors identify subsets of
obstetric patients requiring extra vigilance for
prevention, early recognition and intervention
for PASS. However, as noted by others, the risk





The most common sites of infection among
patients with PASS in local studies were
described variably as involving the genital
(39%) [27] and urinary (37%) [35] tracts.
Kramer et al. [30] reported in their national
study that genital tract infections were the most
common, noted in 56% of their patients. No
data on sites of infection were reported on PASS
hospitalizations in the study by Acosta et al.
[32]. Finally, in the national population study
by Bauer et al. [33], the genital tract was the
most common reported site of infection
(56.7%) among PASS hospitalizations. Of note,
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pneumonia was reported in 29.7% of PASS
hospitalizations [33].
Although SIRS has been considered part of
the bedside definition of sepsis in the general
population, it was not validated in obstetric
patients pre- or post-delivery and multiple
investigators have raised concerns about the
appropriateness of its cutoff values, which are
often observed among otherwise healthy
pregnant women [25]. The clinical findings of
PASS include those related to a specific site of
infection. Nevertheless, the site of infection is
often not readily apparent in these patients.
Indeed, Mabie et al. [27] have reported that the
source of infection was not apparent in 44% of
their patients with septic shock.
In addition, patients with PASS can display
findings related to specific organ dysfunction or
failure. Relatively limited data are available on
the type, frequency, and number of failing
organs among women developing PASS.
Respiratory failure was the most common OF
among PASS patients, reported in 44% [27] to
70% [35] in local studies, and 34% in a
population study by Bauer et al. [33]. Renal
failure was reported between 16% [33] to 37%
[35]. Acosta et al. [32] did not describe
systematically the occurrence of failing organs
in their population. Hematological dysfunction
was especially common, ranging between 39%
[27] to 43% [35] of patients in local studies, and
in 19% of PASS hospitalizations in a population-
based investigation [33]. Neurological
dysfunction appears less common, described in
8% [33] of hospitalizations to 11% [27] of
patients, although Snyder et al. [35] reported
‘‘altered mental status’’ in 30% of their patients,
without providing further detail. Only one
study has reported systematically the
distribution of the number of failing organs in
PASS. Snyder et al. [35] found a single OF in
40%, 2 OF in 27% and C3 OF in 33% of their
patients.
Severe sepsis in the obstetric population can
become rapidly fatal. Kramer et al. [30] noted
that the time from the first symptom of
infection to ‘‘full-blown sepsis’’ was\24 h in
39% of their patients and that among women
who died due to severe sepsis, the time from the
onset of infection to death was less than 24 h in
50% of patients. Similarly, Snyder et al. [35]
reported a rapid deterioration among all PASS
patients who died. It has been further noted by
some investigators that a predominant focus on
genital tract sepsis may mislead clinicians in
their assessment of pregnancy-associated
infections [36]. These findings underscore the
need for prompt recognition and timely
effective intervention in patients with PASS.
Because early clinical findings may overlap
those of pregnancy-related physiological
changes [25], while the site of infection may
not be readily apparent [27], heightened level of
suspicion by clinicians is crucial for adequate
care of affected patients.
MICROBIOLOGY OF PREGNANCY-
ASSOCIATED SEVERE SEPSIS
Patient-level data on the pathogens associated
with PASS are limited due to the rarity of this
complication in the obstetric population. Most
of the available data on the antimicrobial
management of PASS have been adapted from
that on the microbiology among infected
obstetric patients who are not necessarily
severely septic. It is presently unknown to
what extent these data apply to PASS
population. When reported, microbiology data
varied across studies. Escherichia coli was the
most common isolate in the study by Mabie
et al. [27], while group A streptococci
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dominated (32%) the isolated pathogens in the
study by Kramer et al. [30]. Microbial isolates
were also reported in 40.4% of PASS
hospitalizations by Bauer et al. [33]. Gram-
negative and Gram-positive bacteria were
evenly reported (49.5% and 46.1%,
respectively). E. coli was the most common
isolate. The investigators did not describe rates
of polymicrobial versus monomicrobial PASS
events.
Infections in the obstetric population are
often described as polymicrobial [25], likely
reflecting the predominance of genital tract
infection. No data are presently available on
site-specific infecting microorganisms in
obstetric patients with sepsis versus severe
sepsis. Similarly, contemporary trends in
antimicrobial resistance of infecting
microorganisms among patients with maternal
sepsis and specifically PASS have not been




Early recognition of possible severe sepsis,
coupled with timely effective interventions are
key elements in the management of PASS,
similarly to those in the general population
with severe sepsis. Because, as noted earlier, the
initial clinical manifestations of PASS may
overlap those of pregnancy-related
physiological changes [24, 25], while the
findings pointing to the source of infection
may not be readily apparent, heightened level
of suspicion by clinicians is essential to assure
timely care.
The specific components of care of patients
with PASS are commonly based on the
periodically revised practice guidelines of the
SSC [17], which include evolving research data
on severe sepsis. However, the SSC diagnostic
criteria and care elements were never validated
in the obstetric population and pregnant
women were commonly excluded from severe
sepsis trials [15, 37]. Early antimicrobial
therapy, prompt circulatory resuscitation in
patients with hypotension or elevated lactate,
and effective early source control of infection
are the main elements of the initial care of PASS,
with further organ-specific support in
individual patients. Patients with PASS are
commonly managed in an ICU.
Empiric broad-spectrum antimicrobial
therapy should be initiated within the first
60 min of the clinical manifestations of PASS
[17] (once the patient is in a healthcare
setting), adjusted for the suspected site of
infection (if apparent) and selected with
knowledge of the local antimicrobial
resistance patterns of potential pathogens. A
recent report by Ferrer et al. [38] has confirmed
the earlier findings by Kumar et al. [16],
demonstrating in a large multinational dataset
that each hour of delay in antimicrobial
therapy is associated with adjusted linear rise
in patient mortality for both severe sepsis and
septic shock [38]. The absolute risk of death
with antibiotic delay was lower than that
reported by Kumar et al. [16], likely reflecting
in part the markedly reduced case fatality in
contemporary severely septic patients and
increased adherence to other components of
the early support of these patients. Because
genital tract infections are a common source of
PASS, and obstetric infections tend to be
polymicrobial [25], initial broad-spectrum
antimicrobial therapy should include coverage
of Gram-positive, Gram-negative, and
anaerobic bacteria [25]. Blood and site-specific
cultures should be obtained prior to staring
antibiotics, but should not impede their timely
administration.
Infect Dis Ther (2014) 3:175–189 183
Circulatory resuscitation should be promptly
started in hypotensive patients and in those
with occult hypoperfusion, manifested by
elevated serum lactate. Nevertheless, nearly
50% of hemodynamically unstable patients are
not fluid-responsive (that is, do not show
increase of their cardiac output or stroke
volume in response to acute fluid
resuscitation) [39] and recent reports indicate
that increased positive fluid balance is
associated with increased risk of death in
patients with septic shock [40]. The dynamic
rise of blood volume during pregnancy and its
subsequent change postpartum [24] add to the
complexity of targeted volume resuscitation of
women developing PASS and underscore the
need to assure appropriate circulatory volume
support, while minimizing harm. Further
studies are urgently needed to better define
optimal circulatory volume resuscitation
approach in obstetric patients with shock and
specifically those developing PASS. Isotonic
crystalloids are used for circulatory
resuscitation of severe sepsis, as colloids
(albumin) were not shown to be more
beneficial [41], and starches should be avoided
due to increased risk of acute kidney injury and
mortality [17]. Catecholamines should be added
for persistent hypotension despite intravenous
volume resuscitation. Norepinephrine is
considered the vasopressor of choice in septic
shock [17] in the general population, but its role
versus other vasopressors has not been
systematically examined in the obstetric
population.
As noted earlier, a protocolized resuscitative
approach, EGDT [15], including placement of a
central venous catheter and targeting
resuscitation to achieve specific end-points of
central venous pressure and central venous
oxygen saturation, has been recommended in
patients with overt shock or lactate
levels C4 mmol/l [17]. However, a recent
multicenter study of patients with septic shock
[37] found that non-protocolized care can result
in similar patient outcomes as EGDT or
protocolized care, as long as there is early
recognition of severe sepsis, and patients
receive prompt administration of appropriate
antibiotics, and early intravenous fluid
resuscitation, coupled with remainder of the
non-resuscitative care elements recommended
by the SSC [17]. Respiratory and other systemic
support should be provided depending on
occurrence and severity of other organ
dysfunction or failure [17]. Surgical or other
interventional source control of infection
should be provided early in selected patients
with PASS. Mabie et al. [27] have reported the
need for surgical intervention in 44.4% of their
septic shock patients.
Mechanical ventilation is often required for
severely septic patients developing respiratory
failure. A lung-protective strategy has been
recommended in patients with acute
respiratory distress syndrome [17]. This
approach involves among other components
use of lower tidal volume and allowing
‘‘permissive hypercarbia’’. However, while
avoiding excessively high, non-physiological
tidal volume would likely be beneficial in
mechanically ventilated obstetric patients,
pregnant women were excluded from studies
on the acute respiratory distress syndrome.
Hypercarbia is generally well tolerated by non-
obstetric, mechanically ventilated patients with
acute respiratory distress syndrome and has
been demonstrated to possibly have systemic
organ-protective effects [42]. However, the
balance between avoiding hypercarbia in
mechanically ventilated pregnant patients and
the adverse pulmonary and systemic
consequences associated with overly aggressive
augmented ventilation have not been
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determined in this population and require
further study.
Among women with PASS developing prior
to delivery, prompt initiation of fetal
monitoring and consideration of timing and
type of delivery should be integral parts of care.
However, delivery was not shown to improve
maternal outcomes among septic women [43].
The details of fetal care in women with severe
sepsis have been described elsewhere [25].
While data on the general elements of care of
severe sepsis in the general population and in
PASS patients have been readily accessible to
clinicians (in developed countries), many
challenges remain in the care of PASS.
Multiple investigators have described prevalent
substandard care in women with PASS. Kramer
et al. [30] have found that among women who
died due to severe sepsis, a substandard care
analysis showed delayed in diagnosis and/or
therapy in 38% of patients. In the report of the
confidential enquiry on maternal deaths in the
UK, Cantwell et al. [44] reported that
‘‘substandard care’’ occurred in 69% of
patients. The authors recommended ‘‘going
back to the basics’’, including among other
recommendations, mandatory, audited training
of all clinical staff in the identification and
initial management of pregnancy-associated
sepsis.
Because of the rarity of PASS, with an
estimate of up to around 2,000 events per year
in the US (when using the highest population-
based incidence data to date [32]), most
clinicians and hospitals are unlikely to
encounter even a single patient with PASS in a
given year. The rarity of PASS, coupled with its
demonstrated risk of a rapidly fatal course,
underscores the ongoing challenges in





Patients with PASS are often managed in an ICU
[27, 30, 31, 35]. Kramer et al. [30] reported ICU
utilization in 79% of their patients with severe
sepsis. However, as noted earlier, it is possible
that septic patients without OF were included in
their analysis, and ICU admission among septic
obstetric patients is an inaccurate surrogate
measure for a case definition of PASS [31].
None of the other reports on PASS described
ICU utilization among the examined cohorts.
Use of life support interventions was not
systematically described in available reports on
PASS. Mechanical ventilation was used in 7.6%
of PASS hospitalizations reported by Acosta
et al. [32], although the reported rate is likely
an underestimate due to the noted overly broad
case definition of PASS. On the other hand,
mechanical ventilation was used in 52% of
septic shock hospitalizations reported in the
same study, based on an ‘‘explicit’’ code-based
definition of septic shock (i.e., use of only a
specific ICD-9-CM code for septic shock, rather
than including in addition a combination of
codes for sepsis/infection and OF) [32]. Bauer
et al. [33] described use of mechanical
ventilation for C96 h in about 25% of their
patients. Hemodialysis use was reported in
about 5% [33] of PASS hospitalizations to 10%
[35] of PASS patients. Further studies are
required on the use of life support and other
interventions in patients developing PASS.
Hospital length of stay among PASS patients
was reported infrequently, ranging from 10 to
19 days in the study by Kramer et al. [30].
Acosta et al. [32] reported a relatively short
median length of stay of 5 days in their non-
shock PASS hospitalizations, likely reflecting
Infect Dis Ther (2014) 3:175–189 185
case misclassification. The average ICU length
of stay among survivors of septic shock was
15.1 days in the study by Mabie et al. [27]. None
of the reports to date have addressed the fiscal
toll of PASS. Further studies are needed to better
understand the contemporary resource
utilization in PASS patients.
OUTCOMES OF PREGNANCY-
ASSOCIATED SEVERE SEPSIS
The case fatality of PASS has varied in available
reports. When reported, data were restricted to
hospital mortality. Among patients with septic
shock, reported case fatality has ranged from
28% [27] to 33% [35]. Using an ‘‘explicit’’ ICD-9-
CM code to define septic shock, Acosta et al.
[32] reported case fatality of 14.3%. Case fatality
of PASS ranged from 10% [35] to 17.6% [28] in
local studies. Kramer et al. [30] reported case
fatality of 7.7% in a national study of severe
sepsis. As noted earlier, their findings should be
interpreted with caution due to multiple
methodological limitations. Similarly, an
overly broad and non-specific case definition
of PASS likely explains the remarkably low
hospital mortality of 0.8% (1.8%, including
septic shock) reported by Acosta et al. [32]. In
the largest study to date on PASS by Bauer et al.
[33], the authors did not report the case fatality
of PASS hospitalizations. Rather, they described
case fatality of 3.2% for all maternal sepsis (i.e.,
both non-severe sepsis and PASS). The authors
described a rising mortality rate by 10% per
year, between 1998 and 2008 for all sepsis
hospitalizations.
The reported case fatality of PASS appears
markedly lower than that observed in the
general population with severe sepsis [4, 5].
Several investigators have suggested that
younger age and the generally healthy
obstetric population may explain these
observations [25, 40]. However, there have
been no reports to date on direct comparisons
between PASS patients and contemporaneous,
similarly managed, age-similar, non-pregnant
women with or without chronic comorbidities.
Thus, it is unclear whether the low case fatality
of PASS is related to a different response to
infection and therapy in obstetric patients than
among their non-pregnant and otherwise
healthy counterparts.
The increasing mortality rate of all maternal
sepsis, reported by Bauer et al. [33], likely
reflects the increasing incidence of PASS
reported by the investigators over study
period. The authors noted that the incidence
of overall sepsis remained stable, while both the
incidence of PASS and sepsis-related mortality
rate rose at the same annual rate [33]. While
specific data were not provided by the
investigators, their findings suggest a
possibility of stable case fatality over study
period. Moreover, other available reports do
not clearly indicate decreasing case fatality of
PASS over time. If the aforementioned postulate
is correct, the results stand in sharp contrast
with reports on severe sepsis in the general
population, which have consistently reported
decreasing case fatality over the past decade,
possibly reflecting in part improved care, in an
increasingly aging and sicker population [4, 5].
Indeed, because the code-based approach used
by Bauer et al. [33] to identify hospitalizations
with severe sepsis was similar to that employed
by other investigators in study of severe sepsis
in the general population [4, 5], the findings of
the former cannot be readily dismissed as
caused by case misclassification. If the case
fatality of PASS has remained unchanged, the
source of this trend would require further
investigation. The factors proposed for
increasing the incidence of PASS (i.e., rising
rates of obesity, older maternal age, and
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possibly increasing associated burden of chronic
illness) may have contributed to the postulated
lack of decrease in case fatality, though their
rates among PASS hospitalizations were not
trended over the study period examined by
Bauer et al. [33]. However, the contemporary
prevalent substandard care noted by other
investigators [30, 35, 40], with delayed
recognition and therapy in PASS patients, in
contrast with the improving care practices in
the general population with severe sepsis [18],
has likely played a substantial part. None of the
studies to date have described predictors of
mortality of patients developing PASS, likely in
part due the very small number of mortality
outcomes inmost reports. Further research is
required to better identify patients with PASS
with increased risk of death to better target
preventive and therapeutic interventions.
Severe sepsis can be associated with multiple
long-term sequelae among survivors, including
higher long-term mortality than that of the
general population, lingering cognitive and
physical dysfunction, as well as mental health
sequelae, including depression, anxiety, and
post-traumatic stress disorder [8, 45, 46]. None
of the reports to date on PASS have described
systematically the hospital disposition among
survivors or their long-term clinical course.
Further studies are urgently needed to better
understand the post-hospitalization outcomes
of survivors of maternal severe sepsis, to better
address prevention and need for long-term care
interventions.
CONCLUSION
PASS is a rare, but likely rising complication in
some developed countries, while there is lack of
data on its occurrence in developing countries.
PASS has been infrequently described and
multiple methodological limitations affect the
interpretation of the varying epidemiological,
clinical, resource utilization and outcome
characteristics described by investigators to
date. PASS is more likely to develop among
minority women, the uninsured, those with
chronic illness, and following invasive
interventions. The genital tract is the most
common reported site of infection. However,
other, non-obstetric, sites of infection should be
considered, though the site of infection may
often not be readily apparent. Although the
reported case fatality is lower compared with
the general population with severe sepsis, PASS
can be rapidly fatal. Because of the overlap
between some of the early clinical
manifestations of PASS and those of normal
pregnancy-related physiological changes, and
the rarity of this condition, high level of
clinicians’ vigilance is crucial for assuring early
recognition and timely intervention. Future
studies are urgently needed to better
understand the burden of PASS across the
spectrum of pregnancy outcomes, in both
developed and developing countries, to
improve systemic approach to assure effective
care, and for improved insight into its long-
term sequelae.
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